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Resum. Cada vegada és més evident que el model actual de 
recursos i desenvolupament no és sostenible. En aquest con­
text, l’assessorament en tecnologia sanitària (HTA), un camp 
multidisciplinari d’anàlisi de polítiques que examina les impli­
cacions mèdiques, econòmiques, socials i ètiques de la tec­
nologia mèdica en l’assistència sanitària, està guanyant im­
portància. Com que proporciona eines que permeten esbrinar 
el valor de la innovació, pot assessorar en la presa de decisi­
ons en el sistema de salut, en l’àmbit clínic, de recerca i de 
desenvolupament. La sostenibilitat del sistema sanitari està 
fortament relacionada amb la responsabilitat social i hem de 
treballar perquè hi hagi aliances entre el sector públic i privat, 
i tornar­nos més eficaços a l’hora d’integrar innovacions soci­
als, organitzatives i polítiques per tal d’oferir la millor qualitat 
d’assistència sanitària que el sistema es pugui permetre.
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Summary. It is becoming increasingly clear that the current 
resource and development model is an unsustainable one. 
Health technology assessment (HTA), a multi­disciplinary field 
of policy analysis that examines the medical, economic, social, 
and ethical implications of medical technology in healthcare, is 
gaining importance in this context. By providing tools with 
which to scrutinise the value of innovation, it can inform deci­
sion­making in the healthcare system, at the clinical, research 
and development levels. Sustainability of the healthcare sys­
tem is strongly related to social responsibility, and we have to 
work towards more effective public­private partnerships, and 
become more adept at integrating social, organisational and 
policy innovations in order to deliver the highest quality of 
healthcare that the system can afford. 
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The context: pressures and drivers of the health 
system
Healthcare policymakers and providers are under pressure 
from various sources. Public expectations, changes socio­de­
mographics, disease patterns, risk factors and scientific knowl­
edge, the globalization of information on healthcare systems, 
increased patient participation, pressures to achieve financial 
sustainability and transparency, and the growing awareness of 
the need for evidence­based decision­making in healthcare are 
just a few of the most important issues that contribute to in­
creasing pressure on the health system. 
But what are the pressures on health industries? There are 
legitimate pressures, such as increased scientific scrutiny of 
innovations, but there are also pricing pressures, the threat of 
biogenerics and biosimilars, the consequences of the loss of 
patents, obsolete commercial models, and inflexible costs 
structures. It is becomingly increasingly clear that the current 
resource and development model is an unsustainable one. It 
is also clear that society’s trust of the pharmaceutical indus­
try has eroded. 
In this context, there is a sense of change in health sys­
tems as they are once again evolving. What are the drivers of 
these changes? First, of course, there is innovation in bio­
medical science. Thanks to complex systems biology and 
molecular biology, to cell, gene, and enzyme therapy, and to 
tissue engineering, for example, we have begun to under­
stand health and disease in a new way, one that is certainly 
very different from how we defined medicine just a few years 
ago. Moreover, personalised, or stratified, medicine, through 
genetic research and molecular diagnostics, is changing the 
paradigms of biomedical and health science research. 
But there are also drivers in the healthcare system; these are 
related to the coverage and provision of healthcare. Currently, 
there is a debate as to whether we should push for governance 
or managerialism, in other words, for more strategic or more 
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tactical approaches. I think we have to do both. But the deci­
sion strongly influences the direction in which health systems 
evolve. Whether doctors can reasonably be expected to be­
come leaders, not just healthcare workers, is another matter of 
important debate, raising questions about quality and efficien­
cy, but also about professional solidarity and ethical impera­
tives. Then we have the adversarial relationship between the 
public and private sectors. I believe that in response to the 
need for cooperation in matters involving social and institution­
al responsibility, new public­private partnerships will develop. 
There is also the driving pressure for healthcare accountability 
and last but not least, health technology assessment. 
Personalised medicine and health technology 
assessment
Health technology assessment (HTA) is a growing movement 
all over the world. Although it started just a few years ago, it is 
now a new paradigm in healthcare. But, depending on who 
you ask, there are different interpretations about what HTA is. 
For healthcare policy makers and providers, HTA is a tool 
with which to scrutinise the value of innovation. How? By 
looking at the scientific evidence in a systematic and exhaus­
tive way and then trying to understand the quality of the evi­
dence, whether published or not, in relation to the projected 
costs. This information can inform decision­making in the 
healthcare system, at the clinical, research and development 
levels. However, the health industry has different perceptions 
of HTA, as an instrument that either poses barriers to innova­
tions or advocates cost­saving measures. 
The current reality, not only for personalised medicine but 
for every innovation of interest to healthcare systems and in­
dustry developers, is that it is important to recognise that an 
innovation must be more than a scientific novelty; rather, it 
must, for example, be able to provide therapeutic added value 
superior to that of already available alternatives or standards 
of care. Otherwise, it will enter or be maintained in the health­
care market only with difficulty. Growing scientific knowledge 
often results in our confusion, as the ‘yes’ or ‘no’ responses of 
governments or HTA agencies no longer suffice. Nowadays, 
the answer is more typically something like, ‘yes, but…’ Or 
more specifically, ‘I allow you to enter the market but with a 
policy of coverage with evidence development.’ This is a type 
of conditional coverage in which payers agree to cover new 
medical technologies, provided that patients receiving care 
that makes use of those technologies are enrolled in a clinical 
study to generate the additional benefit and safety information 
needed to make informed coverage decisions. In fact, cover­
age with evidence development is a managed­entry scheme 
designed to address key health policy issues pertaining to the 
increasing cost pressures, uncertain effectiveness, and great­
er patient benefit per unit of currency spent. Knowledge is 
pressuring the system to be more creative, and policies such 
as coverage with evidence development ensure the preserva­
tion of public health safety issues without impeding techno­
logical evolution and innovation. 
The rules on how these policies should be implemented, who 
pays for what, etc. are still not clear, but the outcome is of great 
interest to industry because it offers a path for future investments 
in research and development. Both the healthcare system and 
the healthcare industry are being forced to adapt, which requires 
that they work together. For now, at least, conditional coverage 
linked to evidence development is a way to do so. 
Impacts and difficulties of personalised medicine
Among the impacts of personalised medicine are:
1.  Higher probability of desired outcome with a drug
2.  Low probability of untoward side effects
3.  Preventive strategies
4.  Focused therapies
5.  Potentially better health outcomes
6.  Recognition of the need to change research and health­
care provision paradigms and relationships
7.  Recognition of the need for holistic HTA: clinical, eco­
nomic, social and ethical assessments that include the 
views of patients
8.  Genomics technology that generate massive amounts of 
information
9.  Recognition of the need for alignment between pharma­
ceutical and diagnostics companies
10.  New business models 
11.  The discovery of genes associated with specific diseas­
es, which for patients with rare diseases and subpopula­
tions of those with common diseases offers novel diag­
nostic and treatment strategies 
Among the main difficulties are:
1.  Scientific challenges posed by the lack of validated mo­
lecular markers and consensus regarding the kind of evi­
dence needed to prove their value to HTAs
2.  How do we get this evidence? Who should pay for it?
3.  Operational issues
4.  Economic challenges due to poorly aligned incentives
5.  Ethical dilemmas not systematically addressed
6.  Lack of clarity on how to evaluate clinical validity and util­
ity for decision­making
7.  Lack of a revised regulatory framework
8.  Opposition by healthcare and industry ‘silos’ 
9.  The global recession, which has forced governments to 
reconcile budgetary challenges. Is there a trade­off be­
tween efficiency and solidarity?
Current challenges for industry developers
Below are examples from the field of rare disease, in which I 
work, but they show that even if we are able to identify a rare 
disease component, it does not mean that there are few barri­
ers to entering the market. Figure 1 shows the number of or­
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phan drug designation applications, designations and ap­
proved orphan products per year. Table 1 shows the 
percentage of HTA decisions by different agencies. ‘No’ indi­
cates the percentage of components for which market entry 
was sought but not approved because evidentiary require­
ments were not met.
As industry developers, we need to receive consistent mes­
sages from the healthcare system regarding evidentiary re­
quirements and what is valued by health systems, because this 
will impact drug development plans. We can be very inefficient 
in our development processes and very ineffective. If we do not 
have consistency with respect to the evidence necessary to 
demonstrate the value of a component, then we are lost.
I would like to transmit the importance of harmonising the 
method and the criteria for evidentiary requirements for health­
care systems. In the therapy of rare diseases, and similarly in 
personalised medicine, the challenges for treatment developers 
are in measuring outcomes. In both cases, we are talking about 
small, geographically dispersed populations that present recruit­
ment challenges for clinical trials, in that low prevalence limits the 
ability to perform multiple studies. Also, the heterogeneity of rare 
diseases poses challenges to uniform treatment paradigms and 
to study design. The slow progression of the disease means that 
measurable effects may take years; surrogate endpoints (renal, 
cardiac, neurological disfunctions, among others) are often more 
apparent than final outcomes such as mortality. Furthermore, 
the regulatory agency requirements are not always aligned, nei­
ther are the HTAs. Finally, post­approval commitments to per­
form more real life studies to further understand the clinical out­
comes of therapies require continuous significant investments. 
This means that the standards of evidence­based medicine can­
not be easily achieved, and methodological and health technol­
ogy assessment interpretation and innovation are crucial. 
Final reflections
Here are just three final reflections. The first one is how can 
we keep healthcare systems sustainable in a changing scien­
tific and social context? In my opinion, sustainability is strong­
ly related to social responsibility. We need to avoid the ‘silo’ 
approach and aim towards more collaborative tools and pro­
cesses. We have to be more inclusive, working from more ef­
fective public­private partnerships, with clear rules. Also, we 
have to deliver the highest quality of healthcare that the sys­
tem can afford. We need to have a better vision of integrated 
care and we must become more adept at integrating social, 
organisational and policy innovations, not only technological 
innovations. Technological innovation without the organisa­
tional frameworks that allow its effective and efficient imple­
mentation is a recipe for disaster. 
The second reflection is that we need to keep putting ideas 
into practice. We need to provide the facilities that promote 
creativity and cross­fertilization from the public and private 
sectors. HTA can help us disinvest in what is not effective, 
what is not efficient. Thus, we have to take greater advantage 
of the HTA tools we currently have at our disposal, to make 
informed decisions about investment and disinvestment. And 
we should always keep in mind that compassion and solidar­
ity should be the principal elements in healthcare systems, 
not just in Europe but all over the world. 
My final reflection is that in this era of networks that we live in 
today, health system sustainability means, more than ever, so­
cial responsibility. Moreover, it will mostly depend on the de­
gree of co­responsibility assumed by healthcare stake­holders. 
Table 1. Percentage of HTA decisions
Agency / Institution Yes Yes/Restricted No
National Institute for Health and Care Excellence (NICE) 67 % – 33 %
Pharmaceutical Benefits Advisory Committee (PBAC) 4 % 56 % 40 %
All Wales Medicine Strategy Group (AWMSG) 29 % 29 % 43 %
Scottish Medicines Consortium (SMC) 22 % 32 % 46 %
National Centre for Pharmacoeconomics (NCPE) 40 % – 60 %
CDAC 27 % – 73 %
Fig. 1. Number of orphan drug designation applications, designations, 
and approved orphan products by the FDA Office of Orphan Product 
Development (OOPD) per year.
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